gemcitabine has been researched along with Soft Tissue Neoplasms in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.35) | 18.2507 |
| 2000's | 15 (32.61) | 29.6817 |
| 2010's | 23 (50.00) | 24.3611 |
| 2020's | 6 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, S; Akisue, T; Asanuma, K; Emori, M; Fukuda, H; Furuta, T; Hatano, H; Hiraga, H; Hiraoka, K; Hiruma, T; Iwamoto, Y; Katagiri, H; Kataoka, T; Kawai, A; Kawano, M; Kawashima, H; Machida, R; Matsumoto, Y; Morii, T; Nagano, A; Nakayama, R; Nishida, Y; Okuma, T; Outani, H; Ozaki, T; Suehara, Y; Takenaka, S; Takeyama, M; Tanaka, K; Toguchida, J; Tsukushi, S; Watanuki, M; Yamamoto, T; Yonemoto, T | 1 |
| Blanco-Alcaina, E; Castilla, C; González-Aguilera, C; Hindi, N; López-Álvarez, M; Martín-Broto, J; Martín-Ruiz, M; Mondaza-Hernández, JL; Moura, DS; Ramos, R; Renshaw, M; Sánchez-Bustos, P | 1 |
| Alameda, M; Espinosa, E; Feliu, J; Gallego, A; Gutierrez-Sainz, L; Martinez-Fdez, S; Martinez-Marin, V; Martinez-Recio, S; Mendiola, M; Pedregosa-Barbas, J; Peña, J; Perez-Wert, P; Pertejo-Fernandez, A; Redondo, A; Villamayor, J; Viñal, D; Zamora, P | 1 |
| Barwad, A; Bhatnagar, S; Bhoriwal, S; Dhamija, E; Kumar, A; Mridha, AR; Rastogi, S; Shamim, SA; Tansir, G | 1 |
| Cheng, J; Feldman, R; Fuks, Z; Fuller, J; Kolesnick, R; Owa, T; Tap, W | 1 |
| Benson, C; Cojocaru, E; Fisher, C; Gennatas, S; Huang, P; Jones, RL; Messiou, C; Miah, AB; Thway, K; Zaidi, S | 1 |
| Chiba, N; Imai, H; Ishioka, C; Komine, K; Mori, T; Ohori, H; Okada, Y; Saijo, K; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S | 1 |
| Algéo, MP; Bourdon, A; Chaire, V; Cousin, S; Italiano, A; Laroche-Clary, A; Le Loarer, F; Lucchesi, C; Rey, C; Savina, A; Shutzman, J; Toulmonde, M; Vélasco, V; Verbeke, S | 1 |
| Bartolazzi, A; D'Arino, A; Federico, A; Magri, F; Muscianese, M; Pigliacelli, F; Pranteda, G | 1 |
| Ahn, JB; Choi, YD; Chung, HC; Han, JW; Heo, SJ; Hur, H; Kim, HS; Kim, JH; Kim, KS; Kim, S; Kim, SH; Kim, SK; Lee, YH; Noh, SH; Park, HS; Rha, SY; Shin, KH; Suh, JS | 1 |
| Trent, JC; Van Tine, BA | 1 |
| Constantinidou, A; Jones, RL; Loggers, E; Pollack, S; Rodler, E | 1 |
| Egerer, G; Ho, AD; Kosely, F; Schmier, JW; Schmitt, T; Wuchter, P | 1 |
| Bar-Sela, G; Miller, RC; Novotny, PJ; Sio, TT; Sohawon, S; Thariat, J; Van Houtte, P; Vu, CC | 1 |
| Araki, N; Fukuda, H; Hiraga, H; Iwamoto, Y; Kataoka, K; Kawai, A; Kimura, A; Matsumine, A; Matsunobu, T; Mizusawa, J; Oda, Y; Tanaka, K | 1 |
| Grignani, G; Martín-Broto, J; Reichardt, P; Schuler, M | 1 |
| Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L | 1 |
| Bouvet, M; Chishima, T; Endo, I; Hiroshima, Y; Hoffman, RM; Ichikawa, Y; Maawy, A; Matsuyama, R; Mii, S; Miwa, S; Momiyama, M; Mori, R; Murakami, T; Tanaka, K; Uehara, F; Yamamoto, M; Yano, S; Zhang, N; Zhang, Y; Zhao, M | 1 |
| Chang, J; Hong, X; Luo, Z; Peng, W; Wang, H; Wang, J; Wu, X; Yu, H; Zhang, X | 1 |
| Allen-Auerbach, MS; Benz, MR; Chow, K; Czernin, J; Dry, SM; Eckardt, JJ; Eilber, FC; Elashoff, D; Evilevitch, V; Phelps, ME; Tap, WD; Weber, WA | 1 |
| Bui-Nguyen, B; Italiano, A; Toulmonde, M | 1 |
| Hensley, ML | 1 |
| Contreras Ibáñez, JA; Díaz Gómez, L; Navas García, N | 1 |
| Buesa, JM; Carrasco, JA; Casado, A; Cruz, J; Cubedo, R; de Andrés, R; De Juan, A; Fra, J; García-Del-Muro, X; Gómez-España, A; Laínez, N; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Meana, A; Pericay, C; Poveda, A; Rubió, J | 1 |
| Arias-Pulido, H; Bocklage, T; Cerilli, LA; Eberhardt, S; Lee, SJ; Movva, S; Muller, CY; Purdy, M; Quinn, R; Rabinowitz, I; Schmit, B; Snyder, D; Verschraegen, CF | 1 |
| Movva, S; Verschraegen, C | 1 |
| Chen, Y; Shi, Y; Wang, C; Yang, Y | 1 |
| Akasbi, Y; Arifi, S; Boutayeb, F; El Idrissi, M; El Mesbahi, O; El Mrini, A; Shimi, M | 1 |
| Issels, RD; Lindner, LH | 1 |
| Bahleda, R; Blay, JY; Dieras, V; LoRusso, P; Macaulay, VM; Mery-Mignard, D; Middleton, MR; Protheroe, AS; Sessa, C; Soria, JC; Tolcher, A | 1 |
| Cognetti, F; Felici, A; Gelibter, A; Nardoni, C; Serrone, L | 1 |
| Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N | 1 |
| Baker, LH; Biermann, JS; Couwlier, C; Lee, JS; Leu, KM; Ostruszka, LJ; Palazzolo, K; Shewach, D; Sondak, V; Zalupski, M | 1 |
| Argani, P; Brinker, DA; Haas, M; Montgomery, EA; Wu, J | 1 |
| Bach, AM; Choi, J; Currie, VE; D'Andrea, GM; Hudis, CA; Lake, DE; Moasser, MM; Modi, S; Norton, L; Panageas, KS; Seidman, AD; Theodoulou, M | 1 |
| Azemar, M; Bokemeyer, C; Hartmann, JT; Horger, M; Huober, J; Jakob, A; Kanz, L; Oechsle, K | 1 |
| Arias de la Vega, F; Gómez Dorronsoro, ML; Jiménez, FJ | 1 |
| Balañá, C; Buesa, JM; Casado, A; Esteban, E; Fra, J; García Del Muro, J; López-Pousa, A; Losa, R; Martín, J; Martínez-Trufero, J; Maurel, J; Poveda, A; Sierra, M | 1 |
| Demetri, GD; Desai, J; Dileo, P; George, S; Harmon, DC; Morgan, JA; Polson, K; Quigley, MT; Salesi, JM; Zahrieh, D | 1 |
| Cercato, MC; Ciccarese, M; Cognetti, F; Di Filippo, F; Ferraresi, V; Giannarelli, D; Nuzzo, C; Zeuli, M | 1 |
| Boven, E; Braakhuis, BJ; Peters, GJ; Ruiz van Haperen, VW; Veerman, G | 1 |
| Boven, E; Erkelens, CA; Hatty, SA; Pinedo, HM; Schipper, H | 1 |
| Ariad, S; Fenig, E; Flusser, G; Inbar, M; Issakov, J; Kollender, Y; Meller, I; Merimsky, O; Neuman, G; Sapir, D; Weil-Ben-Arush, M | 1 |
| Dietzmann, A; Genvresse, I; Grunewald, R; Koschuth, A; Possinger, K; Späth-Schwalbe, E | 1 |
| Benjamin, RS; Burgess, MA; Gandhi, V; Jenkins, J; Papadopolous, N; Patel, SR; Plager, C; Plunkett, W | 1 |
| Conte, PF; Dani, D; Donati, S; Gennari, A; Giorgetti, A; Landucci, E; Mariani, G; Pisani, P; Poli, M; Puccini, G; Salvadori, B; Salvadori, PA; Sorace, O | 1 |
7 review(s) available for gemcitabine and Soft Tissue Neoplasms
| Article | Year |
|---|---|
The management of pseudomyogenic hemangioendothelioma of the foot: A case report and review of the literature.
Topics: Adolescent; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Deoxycytidine; Foot; Gemcitabine; Hemangioendothelioma, Epithelioid; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Soft Tissue Neoplasms; Treatment Outcome | 2018 |
The evolution of systemic therapy in sarcoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chordoma; Deoxycytidine; Dermatofibrosarcoma; Dioxoles; Docetaxel; Drug Resistance, Neoplasm; Gemcitabine; Hemangiosarcoma; Humans; Osteosarcoma; Proteasome Inhibitors; Receptor, IGF Type 1; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin | 2013 |
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2010 |
Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Sarcoma; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2010 |
Systemic management strategies for metastatic soft tissue sarcoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dioxoles; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Lysine; Paclitaxel; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2011 |
Soft-tissue metastasis revealing a pancreatic adenocarcinoma: one case report and a review of literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Buttocks; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Soft Tissue Neoplasms; Thigh | 2012 |
[Soft-tissue sarcoma: recent developments].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Gemcitabine; Humans; Hyperthermia, Induced; Indazoles; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sirolimus; Soft Tissue Neoplasms; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
19 trial(s) available for gemcitabine and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Doxorubicin; Febrile Neutropenia; Gemcitabine; Humans; Ifosfamide; Sarcoma; Soft Tissue Neoplasms | 2022 |
A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Quality of Life; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Treatment Outcome | 2023 |
CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.
Topics: Animals; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Genes, p53; Heterografts; Humans; Mice; Mice, Knockout; Mice, Nude; Mutation; Piperidines; Pyridines; Pyrroles; Soft Tissue Neoplasms; Tumor Suppressor Protein p53 | 2018 |
Gemcitabine and docetaxel for metastatic soft tissue sarcoma - a single center experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2013 |
A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Japan; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Hospitalization; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Michigan; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Radiotherapy, Adjuvant; Sarcoma; Soft Tissue Neoplasms; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2015 |
A Phase II Study of Gemcitabine, Vincristine, and Cisplatin As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome; Vincristine; Young Adult | 2015 |
Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Dacarbazine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Spain; Treatment Outcome; Young Adult | 2011 |
Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Proportional Hazards Models; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Taxoids; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Melanoma; Middle Aged; Quinazolines; Receptor, IGF Type 1; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2013 |
Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Heart Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Salvage Therapy; Soft Tissue Neoplasms | 2003 |
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Salvage Therapy; Skin Neoplasms; Soft Tissue Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Vomiting | 2005 |
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms | 2006 |
Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Sarcoma; Soft Tissue Neoplasms | 2006 |
Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; History, 16th Century; History, 17th Century; Humans; Male; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms | 2008 |
Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Bone Neoplasms; Chondrosarcoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Recurrence, Local; Osteosarcoma; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2000 |
Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Female; Gemcitabine; Humans; Ifosfamide; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Safety; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome | 2000 |
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Leiomyosarcoma; Leukocytes, Mononuclear; Male; Middle Aged; Phosphates; Sarcoma; Soft Tissue Neoplasms | 2001 |
20 other study(ies) available for gemcitabine and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas.
Topics: Furans; Gemcitabine; Humans; Ketones; Leiomyosarcoma; Sarcoma; Soft Tissue Neoplasms | 2022 |
Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study.
Topics: Dacarbazine; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms | 2023 |
Enhancement of Soft Tissue Sarcoma Response to Gemcitabine through Timed Administration of a Short-Acting Anti-Angiogenic Agent.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Deoxycytidine; Endothelial Cells; Gemcitabine; Male; Mice; Neovascularization, Pathologic; Phenylurea Compounds; Quinolines; Sarcoma; Soft Tissue Neoplasms; Sphingomyelin Phosphodiesterase; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue.
Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma, Clear Cell; Soft Tissue Neoplasms | 2020 |
Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2017 |
Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Soft Tissue Neoplasms; Sulfonamides; Young Adult | 2019 |
How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
Topics: Deoxycytidine; Gemcitabine; Humans; Indazoles; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2019 |
Extraskeletal Osteosarcoma: An International Rare Cancer Network Study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Lower Extremity; Male; Methotrexate; Middle Aged; Mitomycin; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Osteosarcoma; Pelvic Neoplasms; Prognosis; Radiotherapy; Rare Diseases; Retroperitoneal Neoplasms; Retrospective Studies; Soft Tissue Neoplasms; Tumor Burden; Young Adult | 2016 |
Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Contraindications; Dacarbazine; Deoxycytidine; Dioxoles; Female; Femoral Neoplasms; Gemcitabine; Humans; Hysterectomy; Ifosfamide; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Radionuclide Imaging; Remission Induction; Salvage Therapy; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Thigh; Tomography, X-Ray Computed; Trabectedin; Treatment Outcome; Uterine Neoplasms | 2015 |
Tumor-Targeting Salmonella typhimurium A1-R Arrests a Chemo-Resistant Patient Soft-Tissue Sarcoma in Nude Mice.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Disease Models, Animal; Gemcitabine; Indazoles; Mice; Mice, Nude; Pyrimidines; Salmonella Infections; Salmonella typhimurium; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Doxorubicin; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Prospective Studies; Sarcoma; Sensitivity and Specificity; Soft Tissue Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Mestastatic gastric cancer from malignant fibrous histiocytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dioxoles; Docetaxel; Epirubicin; Fatal Outcome; Gemcitabine; Histiocytoma, Malignant Fibrous; Humans; Ifosfamide; Lung Neoplasms; Male; Soft Tissue Neoplasms; Spinal Neoplasms; Stomach Neoplasms; Taxoids; Tetrahydroisoquinolines; Thigh; Thoracic Vertebrae; Trabectedin | 2011 |
Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Extremities; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Mesna; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Remission Induction; Sarcoma, Synovial; Soft Tissue Neoplasms; Taxoids | 2012 |
Salvage chemotherapy for advanced sarcoma patients: a single-institution experience survey.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2002 |
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Taxoids | 2004 |
Primary alveolar soft part sarcoma (ASPS) of the breast: report of a deceptive case with xanthomatous features confirmed by TFE3 immunohistochemistry and electron microscopy.
Topics: Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Biomarkers, Tumor; Breast Neoplasms; Cytoplasmic Vesicles; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Humans; Microscopy, Electron, Transmission; Sarcoma; Soft Tissue Neoplasms; Transcription Factors; Treatment Outcome; Xanthomatosis | 2005 |
Subcutaneous metastasis as the first manifestation of a solid-pseudopapillary tumor of the pancreas.
Topics: Adenocarcinoma, Clear Cell; Aged; Antimetabolites, Antineoplastic; Arm; Biomarkers; Biomarkers, Tumor; Deoxycytidine; Diagnostic Errors; Female; Gemcitabine; Humans; Keratins; Neoplasm Proteins; Neprilysin; Neuroendocrine Tumors; Pancreatic Neoplasms; Phosphopyruvate Hydratase; Soft Tissue Neoplasms; Subcutaneous Tissue; Vimentin | 2006 |
Schedule-dependent antitumor effect of gemcitabine in in vivo model system.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Squamous Cell; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms | 1995 |
The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 1993 |
Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Monitoring; Epirubicin; Female; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Humans; Liver Neoplasms; Lung Neoplasms; Paclitaxel; Predictive Value of Tests; Radiopharmaceuticals; Remission Induction; Soft Tissue Neoplasms; Survival Analysis; Time Factors; Tomography, Emission-Computed; Treatment Outcome | 2000 |